US 12,404,527 B2
Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells
Pierre-Olivier Duroy, Plan-les-Ouates (CH); Sandra Bosshard, Plan-les-Ouates (CH); Philippe Le Mercier, Plan-les-Ouates (CH); Emanuel Schmid-Siegert, Plan-les-Ouates (CH); and Nicolas Mermod, Plan-les-Ouates (CH)
Assigned to Selexs S.A., Plan-les-Ouates (CH)
Appl. No. 17/417,131
Filed by Selexis S.A., Plan-les-Ouates (CH)
PCT Filed Dec. 20, 2019, PCT No. PCT/EP2019/086873
§ 371(c)(1), (2) Date Jun. 22, 2021,
PCT Pub. No. WO2020/136149, PCT Pub. Date Jul. 2, 2020.
Claims priority of provisional application 62/784,566, filed on Dec. 24, 2018.
Prior Publication US 2022/0090144 A1, Mar. 24, 2022
Int. Cl. C12N 15/90 (2006.01); C07K 14/005 (2006.01); C12N 15/67 (2006.01)
CPC C12N 15/907 (2013.01) [C07K 14/005 (2013.01); C12N 15/67 (2013.01); C12N 2740/10023 (2013.01); C12N 2740/13021 (2013.01); C12N 2740/13022 (2013.01)] 23 Claims
OG exemplary drawing
 
1. An engineered cell comprising:
a genome of the cell, wherein the genome of the cell has been engineered to comprise alterations within
ERV sequences integrated into the genome, wherein the ERV sequences include at least one full-length ERV sequence comprising SEQ ID NO: 3 or a sequence having 95% sequence identity with SEQ ID NO: 3 integrated into the genome, wherein one to twenty of the alternations are within one or more gag sequence of the ERV sequences, and wherein at least one of the alterations is within a gag gene of the at least one full-length ERV sequence resulting in at least one altered full-length ERV sequence.